A comparative evaluation of antimicrobial eye drops cytotoxicity

Abstract

In addition to the spectrum of antibacterial activity of antimicrobial medicines and their pharmacokinetic and pharmacodynamic properties, their safety is also an important issue. Currently, there is no consensus on the fluoroquinolone toxicity. The purpose of this study was to compare in vitro the overall cytotoxic effect of six antibacterial fluoroquinolone eye drops: 1. Cipromed™ (ciprofloxacin 0.3 %; Sentiss Pharma Pvt. Ltd., India); 2. Floxal™ (ofloxacin 0.3 %; Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH, Germany); 3. Oftaquix™ (levofloxacin 0.5 %; Santen Oy, Finland); 4. Signicef® (levofloxacin 0.5 %; Sentiss Pharma Pvt. Ltd., India); 5. Vigamox® (moxifloxacin 0.5 %; Alcon Laboratories, Inc., USA); 6. Zymar® (gatifloxacin 0.3 %; Allergan Sales LLC, USA). The study showed the possibility of using cultured cells for comparative evaluation of cytotoxic effects of various ophthalmic preparations. We found that tested antimicrobial medicines may have a cytostatic effect in vitro and differ in their cytotoxic potential.